Evolus (NASDAQ:EOLS) Earns Buy Rating from HC Wainwright

Evolus (NASDAQ:EOLS)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a report issued on Tuesday, Benzinga reports. They presently have a $27.00 price objective on the stock. HC Wainwright’s target price indicates a potential upside of 108.66% from the company’s current price.

Several other equities research analysts have also commented on the company. Needham & Company LLC restated a “buy” rating and set a $22.00 price target on shares of Evolus in a research note on Wednesday, May 8th. Barclays upgraded Evolus from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $10.00 to $16.00 in a report on Monday, January 29th.

Evolus Price Performance

Evolus stock opened at $12.94 on Tuesday. The company has a debt-to-equity ratio of 6.54, a quick ratio of 2.96 and a current ratio of 3.21. The company has a market cap of $810.04 million, a price-to-earnings ratio of -12.32 and a beta of 1.47. Evolus has a 1 year low of $7.07 and a 1 year high of $15.43. The firm has a 50 day moving average price of $12.99 and a 200 day moving average price of $11.91.

Evolus (NASDAQ:EOLS) last announced its quarterly earnings data on Thursday, March 7th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.05). The firm had revenue of $61.00 million for the quarter, compared to the consensus estimate of $61.14 million. Sell-side analysts predict that Evolus will post -0.61 earnings per share for the current year.

Insider Transactions at Evolus

In other Evolus news, insider Rui Avelar sold 27,603 shares of the company’s stock in a transaction that occurred on Tuesday, March 19th. The stock was sold at an average price of $13.92, for a total value of $384,233.76. Following the transaction, the insider now directly owns 372,288 shares of the company’s stock, valued at approximately $5,182,248.96. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, insider Rui Avelar sold 27,603 shares of the business’s stock in a transaction dated Tuesday, March 19th. The shares were sold at an average price of $13.92, for a total value of $384,233.76. Following the completion of the sale, the insider now owns 372,288 shares of the company’s stock, valued at approximately $5,182,248.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Sandra Beaver sold 5,672 shares of the company’s stock in a transaction dated Tuesday, March 19th. The shares were sold at an average price of $13.92, for a total transaction of $78,954.24. Following the completion of the sale, the chief financial officer now owns 154,201 shares in the company, valued at approximately $2,146,477.92. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 61,628 shares of company stock valued at $830,947. 6.10% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of EOLS. Zimmer Partners LP acquired a new stake in shares of Evolus during the first quarter worth $4,200,000. California State Teachers Retirement System grew its position in shares of Evolus by 1.6% during the 1st quarter. California State Teachers Retirement System now owns 48,109 shares of the company’s stock valued at $674,000 after buying an additional 739 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in Evolus by 4.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 39,882 shares of the company’s stock worth $559,000 after acquiring an additional 1,637 shares during the period. Natixis bought a new position in Evolus in the first quarter worth about $489,000. Finally, Lord Abbett & CO. LLC acquired a new position in Evolus in the first quarter valued at approximately $11,628,000. Institutional investors own 90.69% of the company’s stock.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.